Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study

by Evangelos Terpos, Panagiotis Repousis, Chrysavgi Lalayanni, Evdoxia Hatjiharissi, Theodora Assimakopoulou, Georgios Vassilopoulos, Anastasia Pouli, Emmanouil Spanoudakis, Eurydiki Michalis, Gerassimos Pangalis, Ioannis Ntanasis-Stathopoulos, Christos Poziopoulos, Marie-Christine Kyrtsonis, Vasiliki Pappa, Argiris Symeonidis, Christos Georgopoulos, Panagiotis M. Zikos, Maria Gavriatopoulou, Helen A. Papadaki, Magdalini Dadakaridou, Kiki Karvounis-Marolachakis, Eirini Katodritou
Published 2021-04-01